|Dr. Ian E. Dixon M.A.I.C.D., M.B.A., MBA, Ph.D.||Founder, Technology Co-Founder, CEO MD & Director||429.16k||N/A||N/A|
|Dr. Michael L. West Ph.D.||Chief Technology Officer||196.46k||N/A||1964|
|Mr. David Oxley||Pres of International||344.4k||N/A||N/A|
|Dr. Gregor Lichtfuss M.Sc.||Co-Founder & Bus. Services Mang.||N/A||N/A||N/A|
|Mr. Johannes Muhl||Sr. VP of Fin.||N/A||N/A||N/A|
|Caitlin Gladman||VP of Communications||N/A||N/A||N/A|
|Mr. David James Franks B.Ec, BEc, C.A., CA, F Fin, J.P., JP.||Company Sec.||N/A||N/A||1970|
Exopharm Limited, a clinical-stage biopharmaceutical company, develops transformative medicines based upon exosomes or extracellular vesicles (EVs) in Australia. The company's technology includes extracellular vesicle positioning system that allows specific molecules to be attached to the surface of exosomes to target them to selected tissues, organs, or cell types; LOAD technology platform enables loading active pharmaceutical ingredients into exosomes; and ligand-based exosome affinity purification technology solves the critical bottleneck of exosome isolation and purification. Its engineered EVs medicines are applied in the areas, such as neurology, cardiology, and oncology. Exopharm Limited has research collaboration agreements with Astellas Institute for Regenerative Medicine and Showa Denko Materials Co., Ltd. The company was incorporated in 2013 and is based in Melbourne, Australia.
Exopharm Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.